Topic resource collection
Approved comparison material connected to this topic.
479 resourcesRead both sides
GLP-1 Agonists (Semaglutide, Tirzepatide) Slows gastric emptying, extends satiety signaling, delays ghrelin rebound 15–22% body weight over 68–72 weeks Addresses age-related leptin resistance and compensatory hunger mechanisms Na…
BPC-157 Upregulates VEGF and FGF receptors; accelerates collagen synthesis Tendons, ligaments, GI lining 250–500mcg twice daily, subcutaneous Structural changes visible in 10–14 days Most direct evidence for soft tissue repair—es…
Before reviewing individual peptide mechanisms, understand that research applications differ fundamentally from therapeutic use. The table below compares investigational compounds studied in laboratory models. Not approved treatm…
BPC-157 VEGF upregulation, collagen synthesis 250–500 mcg/day Daily (subcutaneous, injury-proximal) 7–10 days for inflammation reduction Best for localized tendon repair. Direct angiogenic effect TB-500 Actin regulation, fibrobla…
Here's how the three best peptides for eczema differ in mechanism, administration, and clinical evidence: KPV Inhibits NF-κB transcription factor via IKK-β blockade Topical (1–5mg/mL) or subcutaneous Phase 2 human trials (open-la…
Fat Loss Priority Tirzepatide 10–15mg/wk + Tesofensine 0.25–0.5mg/day GLP-1/GIP appetite suppression + monoamine reuptake thermogenesis 12–18% body fat reduction, 20–25% lean mass loss of total weight Weekly (tirzepatide) + daily…
Dihexa HGF mimetic; c-Met receptor activation → synaptogenesis 0.1–2 mg/kg (subcutaneous or oral) Oral: 50–60%; Subcutaneous: ~100% 28 days at 2–8°C Highest potency-per-dose; oral administration viable; limited human safety data …
Cerebrolysin Neurotrophic factor cocktail (NGF, BDNF, GDNF) Multi-pathway neuroprotection 10–30 mL IV, 5 days/week 4–12 weeks Broadest neurotrophic coverage. Supports both neuron survival and axonal regrowth Best for neurodegener…
| Peptide | Primary Mechanism | Sleep Phase Affected | Research Maturity | Typical Dosing Range (Research Models) | Reconstitution Stability | Bottom Line ||—|—|—|—|—|—|| DSIP | Delta-opioid receptor agonism | Slow-wave (NREM Sta…
The table below compares the three most studied anti-inflammatory peptides for gut conditions. Each peptide targets a different mechanism. Selecting the right one requires matching the inflammatory pathway to the peptide's recept…
MK 677 Ghrelin receptor agonist (GHS) Growth hormone → IGF-1 → lipolysis & protein synthesis 10–25 mg oral, daily Best for sustained metabolic optimization and recovery speed. 24-hour GH elevation without pulsatile crashes Hexare…
MK 677 (Ibutamoren) Ghrelin receptor agonist → GH/IGF-1 elevation +1.1kg lean mass over 2 years (JCEM trial) 25mg daily oral Strongest evidence for lean mass increase; requires resistance training for functional strength gains CJ…
Thymalin Thymus restoration, T-cell maturation Immune homeostasis, Treg production, CD4+/CD8+ balance Immune dysfunction, recurrent infections, chronic inflammation Subcutaneous injection Best option for dominant immune dysregula…
Selank GABAergic modulation via enkephalin upregulation Hyperarousal, startle response, autonomic dysregulation Multiple human RCTs in anxiety disorders; PTSD studies pending Strongest evidence for anxiety symptoms; minimal sedat…
CJC-1295 + Ipamorelin GHRH analogue + ghrelin agonist. Stimulates pulsatile GH release, elevates IGF-1, upregulates Leydig cell steroidogenesis 12–16% increase in total testosterone; 16–20% increase in free testosterone (16-week …
Cerebrolysin Mimics NGF/BDNF; increases acetylcholine release from cholinergic neurons 2–4 hours (acute); cumulative after 10+ sessions 30ml IV infusion daily × 10–20 days Crosses via neurotrophic factor receptors Strongest acute…
The table below compares immune-modulating peptides by pathway, target tissue, and documented research outcomes. Thymalin Upregulates thymulin production in thymic epithelial cells Thymus gland, T-cell maturation Restored CD4/CD8…
Pinealon Upregulates AANAT enzyme in pineal cells → increases endogenous melatonin synthesis Moderate (acts within 2–3 weeks) High (sustained endogenous production) Low (no receptor saturation) Best for long-term circadian restor…
Cerebrolysin BDNF/NGF mimetic. Neurotrophic receptor activation Human RCTs in TBI populations Intravenous infusion 12% improvement in favorable outcomes (GOS 4–5) at 6 months in pooled analysis of 2,117 patients Approved for TBI …
This table compares peptide candidates under investigation for anxiolytic effects based on mechanism, bioavailability, administration route, and current evidence quality. Selank Opioid receptor modulation (mu/delta), HPA axis dow…